$LONA·8-K

LeonaBio, Inc. · Mar 19, 4:50 PM ET

Compare

LeonaBio, Inc. 8-K

Research Summary

AI-generated summary

Updated

LeonaBio Approves 2026 Equity Incentive Plan, Increases Authorized Shares

What Happened
LeonaBio, Inc. (LONA) filed an 8-K on March 19, 2026 reporting that stockholders at a special meeting approved the company’s 2026 Equity Incentive Plan and an amendment to increase authorized common shares. The board’s new 2026 Plan was approved for grants of stock options, SARs, restricted stock, RSUs and performance awards, and the company filed a Certificate of Amendment on March 18, 2026 to raise authorized common shares from 90,000,000 to 400,000,000 (total authorized capital stock from 190,000,000 to 500,000,000). The company also received stockholder approval for several share-issuance items related to exercises of warrants held by Sermonix Pharmaceuticals and Perceptive Advisors in accordance with Nasdaq rules. Forms of the plan and standard award agreements were filed as exhibits to the 8-K.

Key Details

  • 2026 Equity Incentive Plan authorized for up to 5,700,000 shares, plus up to 1,300,000 recycled from the prior 2020 Plan; includes an annual increase provision up to 5% of outstanding common stock beginning in FY2027.
  • The prior 2020 Equity Incentive Plan will be closed to future grants; outstanding awards under the 2020 Plan remain unaffected.
  • Stockholders approved issuance of 5,502,402 shares upon exercise of a pre-funded warrant held by Sermonix (Nasdaq Rule 5635(a)(2)). Related shareholder votes also approved potential issuances that could cause Sermonix or Perceptive Advisors to exceed 19.99% ownership (Nasdaq Rule 5635(b)).
  • Vote totals: Proposal to approve the 2026 Plan — For: 4,915,626; Against: 295,038; Abstain: 513,793 (broker non-votes: 1,710,428). Certificate of Amendment increasing authorized shares was filed March 18, 2026.

Why It Matters
These approvals give LeonaBio flexibility to attract and retain employees, directors and consultants via equity awards and to accommodate future financing or strategic needs by increasing authorized shares. For investors, the 2026 Plan and the large increase in authorized shares mean potential future dilution if awards are granted or shares are issued, though the filings note existing awards remain valid and the company must follow Nasdaq rules for large ownership changes. The approvals related to Sermonix and Perceptive address specific warrant exercises and required shareholder consent under Nasdaq listing rules.

Loading document...